Epitan plans AIM listing
Thursday, 31 March, 2005
Melbourne's Epitan is planning to raise up to 15 million pounds (AUD$37 million) in a flotation on London's AIM stock market. EpiTan focuses on dermatology and its main product, Melanotan, helps treat sunburn injury.
The company said its London flotation would raise money to fund further development of Melanotan and increase its international profile. EpiTan is already listed on the Australian stock exchange.
"I am delighted to be able to introduce EpiTan to UK investors, particularly as we expect Europe to be a key market for our lead development product, Melanotan," said chief executive Iain Kirkwood.
Trading in the shares on AIM is due to begin in May. Investment bank Teather & Greenwood is the broker and adviser on the flotation.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
